Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19

NCT04372628 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

452

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Lopinavir/Ritonavir 400 mg/100 mg
OTHER: Placebo

Sponsor

Vanderbilt University Medical Center

Collaborators

[object Object]